Introduction: Urachal carcinoma is characterized by high malignancy, poor prognosis, and late stage of diagnosis. There is a lack of unanimous clinical treatment guidelines. We summarize the characteristics, treatment, and outcomes of urachal carcinoma from our center, hoping to provide a reference for diagnosis and treatment. Methods: We retrospectively analyzed the clinical data of 21 patients with urachal carcinoma who were treated at our center from January 2010 to August 2022, and all patients were followed up. Results: The average survival time was 67.1 ± 9.1 (ranging from 49.3 to 84.9) months. The average relapse-free survival was 48.8 ± 9.9 (ranging from 29.5 to 68.2) months. Six patients received adjuvant therapy, mainly chemotherapy. Five patients died during follow-up. Conclusions: Early physical examination may be helpful for early detection of urachal carcinoma. Surgical treatment is still preferred for localized urachal carcinoma. Lymph node dissection may facilitate accurate staging, and positive margin usually results in a worse prognosis. Adjuvant therapy, mainly chemotherapy, may help improve the prognosis. The application of radiotherapy, targeted therapy, and immunotherapy still needs further exploration.

1.
Begg
RC
.
The urachus: its anatomy, histology and development
.
J Anat
.
1930
;
64
(
Pt 2
):
170
83
.
2.
Johnson
DE
,
Hodge
GB
,
Abdul-Karim
FW
,
Ayala
AG
.
Urachal carcinoma
.
Urology
.
1985
;
26
(
3
):
218
21
.
3.
Sheldon
CA
,
Clayman
RV
,
Gonzalez
R
,
Williams
RD
,
Fraley
EE
.
Malignant urachal lesions
.
J Urol
.
1984
;
131
(
1
):
1
8
.
4.
Szarvas
T
,
Módos
O
,
Niedworok
C
,
Reis
H
,
Szendröi
A
,
Szász
MA
, et al
.
Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases
.
Urol Oncol
.
2016
;
34
(
9
):
388
98
.
5.
Hamilou
Z
,
North
S
,
Canil
C
,
Wood
L
,
Hotte
S
,
Sridhar
SS
, et al
.
Management of urachal cancer: a consensus statement by the Canadian urological association and genitourinary medical oncologists of Canada
.
Can Urol Assoc J
.
2020
;
14
(
3
):
E57
64
.
6.
Duan
F
,
Zhai
W
,
Zhang
B
,
Guo
S
.
Urachal carcinoma: impact of recurrence pattern and lymphadenectomy on long-term outcomes
.
Cancer Med
.
2020
;
9
(
12
):
4166
74
.
7.
Henly
DR
,
Farrow
GM
,
Zincke
H
.
Urachal cancer: role of conservative surgery
.
Urology
.
1993
;
42
(
6
):
635
9
.
8.
Ashley
RA
,
Inman
BA
,
Sebo
TJ
,
Leibovich
BC
,
Blute
ML
,
Kwon
ED
, et al
.
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy
.
Cancer
.
2006
;
107
(
4
):
712
20
.
9.
Bruins
HM
,
Visser
O
,
Ploeg
M
,
Hulsbergen-van de Kaa
CA
,
Kiemeney
LA
,
Witjes
JA
.
The clinical epidemiology of urachal carcinoma: results of a large, population based study
.
J Urol
.
2012
;
188
(
4
):
1102
7
.
10.
Siefker-Radtke
A
.
Urachal adenocarcinoma: a clinician's guide for treatment
.
Semin Oncol
.
2012
;
39
(
5
):
619
24
.
11.
Liu
Z
,
Yu
X
,
Hu
J
,
Li
F
,
Wang
S
.
Umbilicus-sparing laparoscopic versus open approach for treating symptomatic urachal remnants in adults
.
Medicine
.
2018
;
97
(
26
):
e11043
.
12.
Ortiz
SL
,
Alonso Prieto
MA
,
Campanario Pérez
F
,
Alvarez-Silva
I
,
De Cabo Ripoll
M
,
García Díez
F
.
Treatment of urachal disorders: the open and laparoscopic surgery approach
.
Arch Esp Urol
.
2017
;
70
(
3
):
357
60
.
13.
Madeb
R
,
Knopf
JK
,
Nicholson
C
,
Donahue
LA
,
Adcock
B
,
Dever
D
, et al
.
The use of robotically assisted surgery for treating urachal anomalies
.
BJU Int
.
2006
;
98
(
4
):
838
42
.
14.
Stokkel
LE
,
van de Kamp
MW
,
Schaake
EE
,
Boellaard
TN
,
Hendricksen
K
,
van Rhijn
BWG
, et al
.
Robot-assisted partial cystectomy versus open partial cystectomy for patients with urachal cancer
.
Urol Int
.
2022
;
106
(
8
):
840
7
.
15.
Niedworok
C
,
Panitz
M
,
Szarvas
T
,
Reis
H
,
Reis
AC
,
Szendröi
A
, et al
.
Urachal carcinoma of the bladder: impact of clinical and immunohistochemical parameters on prognosis
.
J Urol
.
2016
;
195
(
6
):
1690
6
.
16.
Herr
HW
,
Bochner
BH
,
Sharp
D
,
Dalbagni
G
,
Reuter
VE
.
Urachal carcinoma: contemporary surgical outcomes
.
J Urol
.
2007
;
178
(
1
):
74
8
; discussion 8.
17.
Jia
Z
,
Chang
X
,
Li
X
,
Wang
B
,
Zhang
X
.
Urachal carcinoma: are lymphadenectomy and umbilectomy necessary
.
Med Sci Monit
.
2020
;
26
:
e927913
.
18.
Molina
JR
,
Quevedo
JF
,
Furth
AF
,
Richardson
RL
,
Zincke
H
,
Burch
PA
.
Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases
.
Cancer
.
2007
;
110
(
11
):
2434
40
.
19.
Siefker-Radtke
AO
,
Gee
J
,
Shen
Y
,
Wen
S
,
Daliani
D
,
Millikan
RE
, et al
.
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience
.
J Urol
.
2003
;
169
(
4
):
1295
8
.
20.
Pinthus
JH
,
Haddad
R
,
Trachtenberg
J
,
Holowaty
E
,
Bowler
J
,
Herzenberg
AM
, et al
.
Population based survival data on urachal tumors
.
J Urol
.
2006
;
175
(
6
):
2042
7
; discussion 7.
21.
Mylonas
KS
,
P
OM
,
Ziogas
IA
,
El-Kabab
L
,
Nasioudis
D
.
Malignant urachal neoplasms: a population-based study and systematic review of literature
.
Urol Oncol
.
2017
;
35
(
1
):
33.e11
9
.
22.
Jung
Hyun Ae
,
Sun
Jong-Mu
,
Park
Se Hoon
,
Kwon
Ghee Young
,
Lim
Ho Yeong
.
Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer
.
Chemotherapy
.
2014
;
60
(
2
):
73
80
.
23.
Chen
M
,
Xue
C
,
Huang
RQ
,
Ni
MQ
,
Li
L
,
Li
HF
, et al
.
Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor
.
Front Oncol
.
2021
;
11
:
739134
.
You do not currently have access to this content.